Randomized controlled trials for COVID-19: evaluation of optimal randomization methodologies - need for the data validation of the completed trials, and to improve the ongoing and future randomized trial designs
COVID-19. The Recovery trials showed an Absolute Risk Reduction (ARR) in mortality by 2.8% with Dexamethasone, and the ACTT-1 trial showed that the treatment with Remdesivir reduced the Time to recovery by 4 days. The Hydroxychloroquine and Lopinavir/Ritonavir treatments did not show any mortality b...
- Autores:
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/15716
- Acceso en línea:
- https://doi.org/10.1016/j.ijantimicag.2020.106222
http://hdl.handle.net/20.500.12010/15716
- Palabra clave:
- COVID-19 Randomized Controlled Trial Methodologies
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Abierto (Texto Completo)